[go: up one dir, main page]

WO1996012737A3 - Compositions and treatment for multiple sclerosis - Google Patents

Compositions and treatment for multiple sclerosis Download PDF

Info

Publication number
WO1996012737A3
WO1996012737A3 PCT/US1995/013682 US9513682W WO9612737A3 WO 1996012737 A3 WO1996012737 A3 WO 1996012737A3 US 9513682 W US9513682 W US 9513682W WO 9612737 A3 WO9612737 A3 WO 9612737A3
Authority
WO
WIPO (PCT)
Prior art keywords
disease
multiple sclerosis
compositions
autoantigen
myelin
Prior art date
Application number
PCT/US1995/013682
Other languages
French (fr)
Other versions
WO1996012737A9 (en
WO1996012737A2 (en
Inventor
Dawn Smilek
Michael Samson
Malcolm Gefter
Di-Hwei Hsu
Jia-Dong Shi
Xavier Paliard
Brigitte Devaux
Jonathan Rothbard
Henry Franzen
Original Assignee
Immulogic Pharma Corp
Dawn Smilek
Michael Samson
Malcolm Gefter
Hsu Di Hwei
Shi Jia Dong
Xavier Paliard
Brigitte Devaux
Jonathan Rothbard
Henry Franzen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to SK512-97A priority Critical patent/SK51297A3/en
Priority to AU42782/96A priority patent/AU4278296A/en
Priority to SI9520118A priority patent/SI9520118A/en
Priority to CZ971226A priority patent/CZ122697A3/en
Priority to JP8514109A priority patent/JPH10504039A/en
Priority to BR9509438A priority patent/BR9509438A/en
Application filed by Immulogic Pharma Corp, Dawn Smilek, Michael Samson, Malcolm Gefter, Hsu Di Hwei, Shi Jia Dong, Xavier Paliard, Brigitte Devaux, Jonathan Rothbard, Henry Franzen filed Critical Immulogic Pharma Corp
Priority to EP95941330A priority patent/EP0787147A1/en
Publication of WO1996012737A2 publication Critical patent/WO1996012737A2/en
Publication of WO1996012737A9 publication Critical patent/WO1996012737A9/en
Publication of WO1996012737A3 publication Critical patent/WO1996012737A3/en
Priority to IS4466A priority patent/IS4466A/en
Priority to NO971900A priority patent/NO971900L/en
Priority to FI971750A priority patent/FI971750A7/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Rehabilitation Therapy (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention provides isolated peptides and combinations of peptides derived form myelin autoantigens such as MBP, MOG, PLP, and MAG suitable for treating multiple sclerosis, including prophylactic and therapeutic compositions and methods for preventing or treating multiple sclerosis. Preferred compositions of the invention comprise at least one isolated, purified peptide, free from all other polypeptides or contaminants, the peptide comprising an amino acid sequence, the myelin autoantigen which has T cell activity. A therapeutic composition of the invention is capable of down regulating the autoantigen specific immune response to the myelin autoantigen in a population of humans suffering from, or susceptible to multiple sclerosis, such that disease symptoms are reduced, eliminated, or reversed and/or the onset or progression of disease symptoms is prevented or slowed. Additionally, compositions and methods of the instant invention when administered in an advanced stage of disease, reverse ongoing paralysis or other signs of disease when administered during the acute phase of disease or prevents relapse when administered during remission.
PCT/US1995/013682 1994-10-25 1995-10-25 Compositions and treatment for multiple sclerosis WO1996012737A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
EP95941330A EP0787147A1 (en) 1994-10-25 1995-10-25 Compositions and treatment for multiple sclerosis
AU42782/96A AU4278296A (en) 1994-10-25 1995-10-25 Compositions and treatment for multiple sclerosis
SI9520118A SI9520118A (en) 1994-10-25 1995-10-25 Compositions and treatment for multiple sclerosis
CZ971226A CZ122697A3 (en) 1994-10-25 1995-10-25 Preparations and methods of treating disseminated sclerosis
JP8514109A JPH10504039A (en) 1994-10-25 1995-10-25 Compositions and treatments for multiple sclerosis
SK512-97A SK51297A3 (en) 1994-10-25 1995-10-25 Compositions and treatment for multiple sclerosis
BR9509438A BR9509438A (en) 1994-10-25 1995-10-25 Compositions and treatment for multiple sclerosis
IS4466A IS4466A (en) 1994-10-25 1997-04-17 Composition and treatment for multiple sclerosis
FI971750A FI971750A7 (en) 1994-10-25 1997-04-24 Compositions for multiple sclerosis and its treatment
NO971900A NO971900L (en) 1994-10-25 1997-04-24 Mixtures and treatment of multiple sclerosis

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US32822494A 1994-10-25 1994-10-25
US08/328,224 1994-10-25
US40422895A 1995-03-15 1995-03-15
US08/404,228 1995-03-15

Publications (3)

Publication Number Publication Date
WO1996012737A2 WO1996012737A2 (en) 1996-05-02
WO1996012737A9 WO1996012737A9 (en) 1996-07-18
WO1996012737A3 true WO1996012737A3 (en) 1996-10-10

Family

ID=26986277

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/013682 WO1996012737A2 (en) 1994-10-25 1995-10-25 Compositions and treatment for multiple sclerosis

Country Status (15)

Country Link
EP (1) EP0787147A1 (en)
JP (1) JPH10504039A (en)
AU (1) AU4278296A (en)
BR (1) BR9509438A (en)
CA (1) CA2203629A1 (en)
CZ (1) CZ122697A3 (en)
FI (1) FI971750A7 (en)
HU (1) HUT77047A (en)
IL (1) IL115766A0 (en)
IS (1) IS4466A (en)
NO (1) NO971900L (en)
PL (1) PL324091A1 (en)
SI (1) SI9520118A (en)
SK (1) SK51297A3 (en)
WO (1) WO1996012737A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6252040B1 (en) * 1991-10-22 2001-06-26 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
US6156535A (en) 1995-08-04 2000-12-05 University Of Ottawa Mammalian IAP gene family, primers, probes, and detection methods
EP0888541B1 (en) 1996-03-21 2005-05-25 Circassia Limited Cryptic peptides and method for their identification
WO1998006861A2 (en) * 1996-08-15 1998-02-19 Agrivax Incorporated Delivery of tolerogenic antigens via edible plants or plant-derived products
CA2201841C (en) * 1997-04-04 2010-01-26 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
SE9703287D0 (en) * 1997-09-11 1997-09-11 Astra Ab Peptides
HK1039636A1 (en) * 1998-05-05 2002-05-03 科里克萨公司 Myelin basic protein peptides and uses thereof
US20020072493A1 (en) 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
EP1080110A2 (en) * 1998-05-19 2001-03-07 Yeda Research And Development Co. Ltd. Use of activated t cells, nervous system-specific antigens for treating disorders of the nevrous system
EP1288226A1 (en) * 2001-09-03 2003-03-05 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Modification of the expression levels of Toll-like receptor familiy members for influencing neurodegeneration and neuroprotection in the human central nervous system
GB0202399D0 (en) * 2002-02-01 2002-03-20 Univ Bristol Peptide
CA2480308C (en) 2002-03-27 2011-10-04 Aegera Therapeutics Inc. Antisense iap nucleobase oligomers and uses thereof
DE10230381A1 (en) 2002-07-05 2004-01-22 Institut für Medizintechnologie Magdeburg GmbH, IMTM Use of inhibitors of alanyl aminopeptidases and pharmaceutical compositions comprising them
US8012944B2 (en) 2003-10-30 2011-09-06 Pharmascience Inc. Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent
AU2007351813B2 (en) 2006-10-31 2013-10-10 East Carolina University Fusion proteins comprising an anti-inflammatory cytokine and an antigen for treatment of immune disorders
WO2010024927A2 (en) * 2008-08-28 2010-03-04 The Research Foundation Of State University Of New York Treatment of amyloidoses using myelin basic protein and fragments thereof
WO2010117848A1 (en) * 2009-03-31 2010-10-14 East Carolina University Cytokines and neuroantigens for treatment of immune disorders
DK2488196T3 (en) 2009-10-12 2016-03-14 Lifebio Lab Llc A composition for treating multiple sclerosis
RU2448685C2 (en) * 2009-11-30 2012-04-27 Российская Федерация в лице Министерства промышленности и торговли Российской Федерации Liposomes containing oligopeptides - fragments of myelin basic protein, pharmaceutical composition and method of treating multiple sclerosis
WO2012126118A1 (en) * 2011-03-21 2012-09-27 Atlantic Cancer Research Institute Polypeptides with affinity for heat shock proteins (hsps) and hsp associated complexes (hacs) and their use in diagnosis and therapy
MX2016009102A (en) 2014-01-13 2016-09-09 Berg Llc Enolase 1 (eno1) compositions and uses thereof.
EP4212547A1 (en) 2015-12-03 2023-07-19 Juno Therapeutics, Inc. Modified chimeric receptors and related compositions and methods

Citations (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988010120A1 (en) * 1987-06-24 1988-12-29 Brigham And Women's Hospital Treatment of autoimmune diseases by oral administration of autoantigens
WO1991008760A1 (en) * 1989-12-20 1991-06-27 Brigham And Women's Hospital Improved treatment of autoimmune diseases by aerosol administration of auto antigens
WO1991012816A1 (en) * 1990-03-02 1991-09-05 Autoimmune, Inc. Enhancement of the down-regulation of autoimmune diseases by oral administration of autoantigens
WO1991015225A1 (en) * 1990-03-30 1991-10-17 Brigham And Women's Hospital Multiple sclerosis t-cell receptor
WO1992018150A1 (en) * 1991-04-23 1992-10-29 Anergen, Inc. Mhc conjugates useful in ameliorating autoimmunity
WO1993008212A1 (en) * 1991-10-22 1993-04-29 Warren Kenneth G Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid
WO1993009810A1 (en) * 1991-11-19 1993-05-27 Anergen, Inc. Mhc subunit conjugates useful in ameliorating deleterious immune responses
WO1993016724A1 (en) * 1992-02-28 1993-09-02 Autoimmune, Inc. Bystander suppression of autoimmune diseases
WO1993019178A2 (en) * 1992-03-25 1993-09-30 Immunologic Pharmaceutical Corporation Peptides useful for inducing tolerance
WO1993021222A1 (en) * 1992-04-09 1993-10-28 Autoimmune, Inc. Suppression of t-cell proliferation using peptide fragments of myelin basic protein
WO1993025661A1 (en) * 1992-06-10 1993-12-23 President And Fellows Of Harvard College Heterogeneous proteolipid peptide 139-151-specific t cell clones
WO1994004121A1 (en) * 1992-08-17 1994-03-03 Autoimmune, Inc. Bystander suppression of retroviral-associated neurological disease
WO1995006727A2 (en) * 1993-09-03 1995-03-09 Immulogic Pharmaceutical Corporation Uses of myelin oligodendrocyte glycoprotein and peptide portions thereof in protocols related to autoimmune disease
WO1995007096A1 (en) * 1993-09-06 1995-03-16 La Trobe University Treatment of autoimmune disease
WO1995008572A1 (en) * 1993-09-22 1995-03-30 The Board Of Trustees For The Leland Stanford Junior University Interaction of t-cell receptors and antigen in autoimmune disease
WO1995027499A1 (en) * 1994-04-08 1995-10-19 Brigham And Women's Hospital Treatment of autoimmune disease using oral tolerization and/or type i interferon
WO1995027500A1 (en) * 1994-04-08 1995-10-19 Brigham And Women's Hospital TREATMENT OF AUTOIMMUNE DISEASE USING ORAL TOLERIZATION AND/OR Th2-ENHANCING CYTOKINES
WO1995030435A2 (en) * 1994-05-10 1995-11-16 Immulogic Pharmaceutical Corporation Compositions and treatment for multiple sclerosis
WO1995033997A1 (en) * 1994-06-09 1995-12-14 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Alpha b crystallin for use in diagnosis and therapy of auto-immune diseases in particular multiple sclerosis
WO1996016086A1 (en) * 1994-11-18 1996-05-30 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
WO1996016085A1 (en) * 1994-11-18 1996-05-30 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein

Patent Citations (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988010120A1 (en) * 1987-06-24 1988-12-29 Brigham And Women's Hospital Treatment of autoimmune diseases by oral administration of autoantigens
WO1991008760A1 (en) * 1989-12-20 1991-06-27 Brigham And Women's Hospital Improved treatment of autoimmune diseases by aerosol administration of auto antigens
WO1991012816A1 (en) * 1990-03-02 1991-09-05 Autoimmune, Inc. Enhancement of the down-regulation of autoimmune diseases by oral administration of autoantigens
WO1991015225A1 (en) * 1990-03-30 1991-10-17 Brigham And Women's Hospital Multiple sclerosis t-cell receptor
WO1992018150A1 (en) * 1991-04-23 1992-10-29 Anergen, Inc. Mhc conjugates useful in ameliorating autoimmunity
WO1993008212A1 (en) * 1991-10-22 1993-04-29 Warren Kenneth G Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid
WO1993009810A1 (en) * 1991-11-19 1993-05-27 Anergen, Inc. Mhc subunit conjugates useful in ameliorating deleterious immune responses
WO1993016724A1 (en) * 1992-02-28 1993-09-02 Autoimmune, Inc. Bystander suppression of autoimmune diseases
WO1993019178A2 (en) * 1992-03-25 1993-09-30 Immunologic Pharmaceutical Corporation Peptides useful for inducing tolerance
WO1993021222A1 (en) * 1992-04-09 1993-10-28 Autoimmune, Inc. Suppression of t-cell proliferation using peptide fragments of myelin basic protein
WO1993025661A1 (en) * 1992-06-10 1993-12-23 President And Fellows Of Harvard College Heterogeneous proteolipid peptide 139-151-specific t cell clones
WO1994004121A1 (en) * 1992-08-17 1994-03-03 Autoimmune, Inc. Bystander suppression of retroviral-associated neurological disease
WO1995006727A2 (en) * 1993-09-03 1995-03-09 Immulogic Pharmaceutical Corporation Uses of myelin oligodendrocyte glycoprotein and peptide portions thereof in protocols related to autoimmune disease
WO1995007096A1 (en) * 1993-09-06 1995-03-16 La Trobe University Treatment of autoimmune disease
WO1995008572A1 (en) * 1993-09-22 1995-03-30 The Board Of Trustees For The Leland Stanford Junior University Interaction of t-cell receptors and antigen in autoimmune disease
WO1995027499A1 (en) * 1994-04-08 1995-10-19 Brigham And Women's Hospital Treatment of autoimmune disease using oral tolerization and/or type i interferon
WO1995027500A1 (en) * 1994-04-08 1995-10-19 Brigham And Women's Hospital TREATMENT OF AUTOIMMUNE DISEASE USING ORAL TOLERIZATION AND/OR Th2-ENHANCING CYTOKINES
WO1995030435A2 (en) * 1994-05-10 1995-11-16 Immulogic Pharmaceutical Corporation Compositions and treatment for multiple sclerosis
WO1995033997A1 (en) * 1994-06-09 1995-12-14 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Alpha b crystallin for use in diagnosis and therapy of auto-immune diseases in particular multiple sclerosis
WO1996016086A1 (en) * 1994-11-18 1996-05-30 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
WO1996016085A1 (en) * 1994-11-18 1996-05-30 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein

Non-Patent Citations (20)

* Cited by examiner, † Cited by third party
Title
AL-SABBAGH ET AL: "ANTIGEN-DRIVEN TISSUE-SPECIFIC SUPPRESSION FOLLOWING ORAL TOLERANCE:ORALLY ADMINISTERED MYELIN BASIC PROTEIN SUPPRESSES PROTEOLIPID PROTEIN-INDUCED EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS IN THE SJL MOUSE", EUR.J.IMMUNOL., vol. 24, 1994, pages 2104 - 2109, XP000590820 *
AL-SABBAGH ET AL: "BETA INTERFERON ENHANCES ORAL TOLERANCE TO MBP AND PLP IN EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS", NEUROLOGY, vol. 44, April 1994 (1994-04-01), pages A242, XP002009748 *
BURNS ET AL: "ASSESSMENT OF ANTIGENIC DETERMINANTS FOR THE HUMAN T CELL RESPONSE AGAINST MYELIN BASIC PROTEIN USING OVERLAPPING SYNTHETIC PEPTIDES", J.NEUROIMMUNOL., vol. 31, 1991, pages 105 - 113, XP000567821 *
CHOU ET AL: "MONOCLONAL ANTIBODIES TO HUMAN MYELIN BASIC PROTEIN", J.NEUROCHEM., vol. 46, 1986, pages 47 - 53, XP000567823 *
DE ROSBO ET AL: "REACTIVITY TO MYELIN ANTIGENS IN MULTIPLE SCLEROSIS.PERIPHERAL BLOOD LYMPHOCYTES RESPOND PREDOMINANTLY TO MYELIN OLIGODENDROCYTE GLYCOPROTEIN", CLINICAL INVESTIGATION, vol. 92, 1993, pages 2602 - 2608, XP002001195 *
FRITZ ET AL: "LOCALIZATION OF AN ENCEPHALITOGENIC EPITOPE FOR THE SJL MOUSE IN THE N-TERMINAL REGION OF MYELIN BASIC PROTEIN", J.NEUROIMMUNOL., vol. 26, 1990, pages 239 - 243, XP000567820 *
JANSSON ET AL: "CHRONIC EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS INDUCED BY THE 89-101 MYELIN BASIC PROTEIN PEPTIDE IN B10RIII (H-2R) MICE", EUR.J.IMMUNOL., vol. 21, 1991, pages 693 - 699, XP000590821 *
JOOSTEN ET AL: "DIRECT BINDING OF AUTOIMMUNE DISEASE RELATED T CELL EPITOPES TO PURIFIED LEWIS RAT MHC CLASS II MOLECULES", INT.IMMUNOL., vol. 6, no. 5, May 1994 (1994-05-01), pages 751 - 759, XP000590812 *
KARIN ET AL: "REVERSAL OF EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS BY A SOLUBLE PEPTIDE VARIANT OF A MYELIN BASIC PROTEIN EPITOPE:T CELL RECEPTOR ANTAGONISM AND REDUCTION OF INTERFERON GAMMA AND TUMOR NECROSIS FACTOR ALPHA PRODUCTION", J.EXP.MED., vol. 180, December 1994 (1994-12-01), pages 2227 - 2237, XP000590823 *
KIRA ET AL: "EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS IN RABBITS.A MAJOR ENCEPHALITOGENIC DETERMINANT WITHIN RESIDUES 1-44 OF MYELIN BASIC PROTEIN", J.NEUROIMMUNOL., vol. 12, 1986, pages 183 - 193, XP000567824 *
KUMAR ET LA: "AMINO ACID VARIATIONS AT A SINGLE RESIDUE IN AN AUTOIMMUNE PEPTIDE PROFOUNDLY AFFECT ITS PROPERTIES:T-CELL ACTIVATION,MAJOR HISTOCOMPATIBILITY COMPLEX BINDING,AND ABILITY TO BLOCK EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS", PROC.NATL.ACAD.SCI.USA, vol. 87, 1990, pages 1337 - 1341, XP002001193 *
LASALLE ET AL: "T-CELL PRESENTATION OF ANTIGEN REQUIRES CELL-TO-CELL CONTACT FOR PROLIFERATION AND ANERGY INDUCTION.DIFFERENTIAL MHC REQUIREMENTS FOR SUPERANTIGEN AND AUTOANTIGEN", J.IMMUNOL., vol. 151, no. 2, 15 July 1993 (1993-07-15), pages 649 - 657, XP002009745 *
LEHMANN ET AL: "SPREADING OF T-CELL AUTOIMMUNITY TO CRYPTIC DETERMINANTS OF AN AUTOANTIGEN", NATURE, vol. 358, 1992, pages 155 - 157, XP002009746 *
MARTIN ET AL: "A MYELIN BASIC PROTEIN PEPTIDE IS RECOGNIZED BY CYTOTOXIC T CELLS IN THE CONTEXT OF FOUR HLA-DR TYPES ASSOCIATED WITH MULTIPLE SCLEROSIS", J.EXP.MED., vol. 173, January 1991 (1991-01-01), pages 19 - 24, XP000590824 *
NAG ET AL: "ANTIGENIC PEPTIDE BINDING TO MHC CLASS II MOLECULES AT INCREASED PEPTIDE CONCENTRATIONS", MOL.IMMUNOL., vol. 31, no. 15, 1994, pages 1161 - 1168, XP000590822 *
NAG ET AL: "SEPARATION OF COMPLEXES OF MAJOR HISTOCOMPATIBILITY CLASS II MOLECULES AND KNOWN ANTIGENIC PEPTIDE BY METAL CHELATE AFFINITY CHROMATOGRAPHY", J.IMMUNOL.METHODS., vol. 169, no. 2, 10 March 1994 (1994-03-10), pages 273 - 285, XP002009744 *
OTA ET AL: "T-CELL RECOGNITION OF AN IMMUNODOMINANT MYELIN BASIC PROTEIN EPITOPE IN MULTIPLE SCLEROSIS", NATURE, vol. 346, 1990, pages 183 - 187, XP002001192 *
SHANMUGAM ET AL: "HEALTHY MONOZYGOUS TWINS DO NOT RECOGNIZE IDENTICAL T CELL EPITOPES ON THE MYELIN BASIC PROTEIN AUTOANTIGEN", EUR.J.IMMUNOL., vol. 24, no. 10, 1994, pages 2299 - 2303, XP002001194 *
TAN ET AL: "REGULATION OF THE EFFECTOR STAGES OF EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS VIA NEUROANTIGEN-SPECIFIC TOLERANCE INDUCTION.II.FINE SPECIFICITY OF EFFECTOR T CELL INHIBITION", J.IMMUNOL., vol. 148, 1992, pages 2748 - 2755, XP002009747 *
VALLI ET AL: "BINDING OF MYELIN BASIC PROTEIN PEPTIDES TO HUMAN HISTOCOMPATIBILITY LEUKOCYTE ANTIGEN CLASS II MOLECULES AND THEIR RECOGNITION BY T CELLS FROM MULTIPLE SCLEROSIS PATIENTS", J.CLIN.INVEST., vol. 91, 1993, pages 616 - 628, XP000567819 *

Also Published As

Publication number Publication date
EP0787147A1 (en) 1997-08-06
AU4278296A (en) 1996-05-15
FI971750A7 (en) 1997-06-24
NO971900L (en) 1997-06-25
SI9520118A (en) 1998-08-31
CZ122697A3 (en) 1997-09-17
FI971750A0 (en) 1997-04-24
NO971900D0 (en) 1997-04-24
CA2203629A1 (en) 1996-05-02
PL324091A1 (en) 1998-05-11
IL115766A0 (en) 1996-01-19
JPH10504039A (en) 1998-04-14
BR9509438A (en) 1997-12-23
HUT77047A (en) 1998-03-02
WO1996012737A2 (en) 1996-05-02
SK51297A3 (en) 1998-03-04
IS4466A (en) 1997-04-17

Similar Documents

Publication Publication Date Title
WO1996012737A3 (en) Compositions and treatment for multiple sclerosis
ATE415173T1 (en) PAN DR BINDING PROTEINS TO INCREASE THE IMMUNE RESPONSE
US4818763A (en) Biologically active substance with hormonal properties, production process thereof and utilization of histones for medical purposes
EP1440980A3 (en) Peptide analogs of human myelin basic protein
EP2327712A3 (en) Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides
GR3031919T3 (en) PEPTIDES OF HUMAN p53 PROTEIN FOR USE IN HUMAN T CELL RESPONSE INDUCING COMPOSITIONS, AND HUMAN p53 PROTEIN-SPECIFIC CYTOTOXIC T-LYMPHOCYTES.
CA2314397A1 (en) Novel peptide, apoep1.b, compositions and uses thereof
RU95108217A (en) Defective recombinant adenovirus, cell strain, pharmaceutical composition
RU94046424A (en) Method of separation of dna-ase forms, human dna-ase, pharmaceutical composition, method of dna-ase storage, treatment method
RU98120519A (en) AUTOANTIGEN AND STRUCTURAL-RELATED PROTEINS FOR USE IN IMMUNOTHERAPY OF AUTOIMMUNE DISEASES
ZA956678B (en) Adenovirus comprising a gene encoding glutathione peroxidase
KR0159046B1 (en) Treatment of autoimmune diseases by aerosol administration of autoantigens
AU2750092A (en) Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid
AU579593B2 (en) Novel peptides which are active on the central nervous system and have an action on the cholinergic system
WO1996018646A3 (en) Heat shock protein peptides and methods for modulating autoimmune central nervous system disease
EP0319315A3 (en) The von willebrand factor binding domain of factor viii
Wu et al. Anti-(14–3–3 protein) antibody inhibits stimulation of noradrenaline (norepinephrine) secretion by chromaffin-cell cytosolic proteins
IL88378A (en) Human interferon-gamma binding proteins their manufacture and pharmaceutical compositions comprising them
AU8811298A (en) Novel peptides and polypeptides useful for regenerating the nervous system
NO982463L (en) Use of a combination of pentoxyphylline and type I interferons for the treatment of multiple sclerosis
PT804182E (en) USE OF GABAPENTINE FOR THE TREATMENT OF ANXIETY AND PANIC
BG101846A (en) HUMAN DNase I VARIANTS
AU4712993A (en) New peptides, antibodies raised against peptides and means for blocking said antibodies, application as medicaments, pharmaceutical compositions and utilization methods
NZ334762A (en) Human DNase I variants having binding affinity to actin
JP2005510469A (en) Use of peptides containing post-translational type modifications in the concept of treatment of autoimmune diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
COP Corrected version of pamphlet

Free format text: PAGES 1/21-5/21,8/21,9/21,14/21-16/21 AND 21/21,DRAWINGS,REPLACED BY NEW PAGES BEARING THE SAME NUMBER;AFTER RECTIFICATION OF OBVIOUS ERRORS AS AUTHORIZED BY THE INTERNATIONAL SEARCHING AUTHORITY

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 51297

Country of ref document: SK

Ref document number: PV1997-1226

Country of ref document: CZ

ENP Entry into the national phase

Ref document number: 2203629

Country of ref document: CA

Ref document number: 2203629

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 971750

Country of ref document: FI

Ref document number: 97-00801

Country of ref document: RO

WWE Wipo information: entry into national phase

Ref document number: 1995941330

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 297592

Country of ref document: NZ

WWP Wipo information: published in national office

Ref document number: 1995941330

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV1997-1226

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1995941330

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: PV1997-1226

Country of ref document: CZ